15 February 2024
15 February 2024
As the market is progressively becoming saturated by GLP-1 receptor agonists, companies are investigating alternative mechanisms of action.
The FDA has issued warning letters to two online sellers for selling unapproved versions of semaglutide and tirzepatide.
The efficacy of iloprost in treating severe frostbite was established through an open-label controlled trial in 47 adults.
A bipartisan group of lawmakers is seeking a formal investigation and sanctions against WuXi given alleged connections to the Chinese military.
The partnership will focus on designing molecular glues for unspecified therapeutic targets.
Grifols’s Phase III AdFIrst trial met its primary endpoint.
The move follows a research collaboration initiated in 2023, aimed at harnessing the platform's capabilities for oligonucleotide drug discovery.
LTG-001 is undergoing a Phase I trial to potentially treat acute and chronic pain.
Merging industry-leading business intelligence & award-winning journalism, this is an unrivalled opportunity for engagement with B2B professionals across a network of 40+ leading media websites.
Steer your business strategy with key data and insights from our latest market research reports and company profiles. Not ready to buy? Start small by downloading a sample report first.
Give your business an edge with our leading industry insights.
